Table 1: Baseline clinical characteristics and TAVR procedural data from the coronary angiogram group and the PCI group.

Angiogram group (n = 28)PCI group (n = 13)

Clinical characteristics
 Age (years)72.54 ± 9.0870.31 ± 7.99
 Male14 (50.0)9 (69.2)
 Body mass index (kg/m2)28.94 ± 5.9628.63 ± 5.38
 NYHA functional class III-IV17 (60.7)6 (46.2)
 Diabetes13 (46.4)5 (38.5)
 Hypertension24 (85.7)13 (100)
 Coronary artery disease23 (82.1)13 (100)
 Prior percutaneous coronary intervention15 (53.6)13 (100)
 Prior coronary arterial bypass graft14 (50.0)9 (69.2)
 History of atrial fibrillation4 (14.3)3 (23.1)
 Peripheral vascular disease9 (32.1)7 (53.8)
 Chronic obstructive pulmonary disease7 (25.0)5 (38.5)
 Chronic kidney disease15 (53.6)10 (76.9)
 eGFR (mL/min)60.36 ± 24.6358.47 ± 26.01
 STS-PROM (%)5.25 ± 2.715.89 ± 3.06
 LogEuroSCORE (%)17.22 ± 11.7917.45 ± 12.72
 Left coronary height (mm)12.77 ± 3.2712.32 ± 2.72
 Right coronary height (mm)13.23 ± 3.2014.50 ± 4.59
Aortoventricular angulation (degrees)42.40 ± 7.9743.30 ± 7.50
Procedural characteristics
 Success28 (100)13 (100)
 Approach
  Transfemoral8 (28.6)4 (30.8)
  Nontransfemoral20 (71.4)9 (69.2)
 Prothesis type
  Edwards-SAPIEN12 (42.9)6 (46.2)
  SAPIEN XT16 (57.1)7 (53.8)
 Prothesis size (mm)
  2315 (53.6)5 (38.5)
  2611 (39.3)6 (46.2)
  292 (7.1)2 (15.4)
 THV-coronary ostia position
  Supra-ostial5 (17.8)3 (23.0)
  Ostial level8 (28.6)5 (38.5)
  Infra-ostial15 (53.6)5 (38.5)

Variables are expressed as n (%) or mean ± SD. eGFR = estimated glomerular filtration rate; LogEuroSCORE = logistic EuroSCORE predicted risk of mortality; NYHA = New York Heart Association; STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality; THV = transcatheter heart valve.